Japan approves Tecentriq for NSCLC

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) said Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Tecentriq atezolizumab (MPDL3280A, RG7446) to treat unresectable advanced or recurrent non-small cell lung cancer (NSCLC). Chugai said it is the drug’s first approval in Japan...